NCT03188536 · ADVERSE EVENTS

Adverse events

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) · Source last updated 2020-10-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: From enrollment on 26 July 2017 to last date of assessment 30 January 2019 (Up to 1.5 years)
Other-event reporting threshold: 0%

Data of adverse events or adverse drug reactions were not collected as part of the study database.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Multiple Myeloma (MM) Participants Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.	0 / 0	0 / 0	0 / 276

Group identifiers: EG000: Multiple Myeloma (MM) Participants

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

Data of adverse events or adverse drug reactions were not collected as part of the study database.

event Groups

deaths Num Affected
0
deaths Num At Risk
276
description
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Multiple Myeloma (MM) Participants

frequency Threshold

time Frame

From enrollment on 26 July 2017 to last date of assessment 30 January 2019 (Up to 1.5 years)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice